You are viewing the site in preview mode
Skip to main content
|
Patient and tumor characteristics
|
Entire cohort (N = 59)
|
aPatients included in theefficacy analysis (N = 55)
|
|---|
|
Age at diagnosis (years) – median (range)
|
55 (33–75)
|
55 (33–75)
|
|
Male gender
|
46 (78%)
|
43 (78%)
|
|
Prior nephrectomy
|
56 (95%)
|
52 (95%)
|
|
Prior IO-VEGF combination by category
|
|
IO-Bev
|
35 (59%)
|
33 (60%)
|
|
IO-TKI
|
24 (41%)
|
22 (40%)
|
|
Prior IO-VEGF combinations by regimen
|
|
Atezolizumab and bevacizumab
|
34 (58%)
|
32 (58%)
|
|
Avelumab and axitinib
|
12 (20%)
|
11 (20%)
|
|
Pembrolizumab and lenvatinib
|
8 (14%)
|
7 (13%)
|
|
Pembrolizumab and pazopanib
|
2 (3%)
|
2 (3%)
|
|
Pembrolizumab and axitinib
|
1 (2%)
|
1 (2%)
|
|
Nivolumab and sunitinib
|
1 (2%)
|
1 (2%)
|
|
Nivolumab and bevacizumab
|
1 (2%)
|
1 (2%)
|
|
Reason for discontinuation of IO-VEGF
|
|
Progression of disease
|
55 (93%)
|
51 (93%)
|
|
Toxicity
|
3 (5%)
|
3 (5%)
|
|
Other
|
1 (2%)
|
1 (2%)
|
|
Time from discontinuation of IO-VEGF to start of the next line therapy (days) - median (range)
|
28 (3–574)
|
30 (3–615)
|
|
IMDC risk at the start of next line of therapy
|
|
Favorable
|
13 (22%)
|
11 (20%)
|
|
Intermediate
|
35 (59%)
|
33 (60%)
|
|
Poor
|
11 (19%)
|
11 (20%)
|
|
Post IO-VEGF next line of therapy
|
|
Cabozantinib
|
22 (37%)
|
22 (40%)
|
|
Axitinib
|
18 (31%)
|
18 (33%)
|
|
Pazopanib
|
4 (7%)
|
4 (7%)
|
|
Lenvatinib and everolimus
|
4 (7%)
|
4 (7%)
|
|
mTOR inhibitor monotherapy
|
3 (5%)
|
3 (5%)
|
|
Axitinib and dalantercept (Clinical trial)
|
2 (3%)
|
2 (4%)
|
|
Sunitinib
|
1 (2%)
|
1 (2%)
|
|
Sorafenib
|
1 (2%)
|
1 (2%)
|
|
Unreported clinical trials
|
4 (7%)
|
–
|
|
Number of therapy line post IO-VEGF
|
|
Second
|
42 (71%)
|
39 (71%)
|
|
Third
|
17 (29%)
|
16 (29%)
|
- Abbreviations: IO-VEGF Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy, IO-Bev Immune-Oncology and Bevacizumab, IO-TKI Immune-Oncology and Tyrosine Kinase Inhibitor, IMDC International Metastatic Database Consortium, VEGFR-TKI Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor, mTOR Mammalian Target of Rapamycin
- aPatients enrolled on unreported clinical trials were excluded from the efficacy analysis
